What counts as a microdose of Wegovy, and does the evidence support it?

What the STEP 1 trial tells us about dose and effect

The evidence base for Wegovy was built on a specific titration structure. In the STEP 1 trial (68 weeks, 1,961 adults with obesity or overweight and a weight-related condition) participants followed the licensed schedule up to 2.4 mg weekly. Average body-weight reduction was around 15%, reported in the New England Journal of Medicine. That figure comes from reaching and sustaining the maintenance dose. Sub-therapeutic exposures were not studied as an intervention in their own right.

This matters because the pharmacology of semaglutide is dose-dependent. GLP-1 receptor activation at low doses produces a milder appetite effect; the therapeutic window the trials validated sits between 1.7 mg and 2.4 mg maintenance. Taking a fraction of the 0.25 mg starting dose (the typical range people describe as 'microdosing') places you well below even the starter rung of the licensed ladder.

The starter dose exists specifically to let the body adjust to GI effects, not to treat obesity. Staying there indefinitely, or going lower, has no trial data showing meaningful weight reduction, and if you are wondering whether Wegovy can be microdosed in a way that still delivers results, that page sets out what the evidence does and does not support. A prescriber reading your case will weigh that gap in evidence against whatever you hope to gain.

How people attempt to microdose Wegovy, and where it breaks down

In online forums, 'microdosing' Wegovy usually means one of three things: injecting a partial pen dose by moving the dial below 0.25 mg, splitting a monthly supply across more weeks, or staying permanently at 0.25 mg rather than titrating up. The practical problem is that Wegovy pens are factory-set to deliver fixed doses per the licensed schedule. Attempting to dial below the minimum setting risks inaccurate dosing and potential waste of a medicine that is still in short supply in parts of the UK.

There is a separate (and legitimate) clinical concept of a cautious titration, where a prescriber slows the upward schedule for a patient who is struggling with nausea. That is not microdosing; it is personalised prescribing within the licensed framework, and it happens under supervision. The semaglutide overview on our site covers how the titration schedule works in practice.

People who are curious about whether you can microdose Wegovy and whether a lower-dose approach might suit them are increasingly asking prescribers about it directly. That conversation is worth having, but through a proper consultation, not by self-adjusting at home.

The safety picture below licensed doses

The MHRA's safety monitoring for Wegovy covers the licensed dose range. Below it, the adverse-event profile is largely unknown because the trials did not characterise it. That cuts both ways: sub-licensed doses are not proven dangerous, but they are also not proven safe in this context. The uncertainty is real.

One thing that is well-established across the dose range is that semaglutide slows gastric emptying. Even at low exposures this can affect the absorption of other oral medicines, which is why the NHS England guidance on weight-management injections flags interactions with oral contraceptives and HRT as things to discuss with your prescriber. That flag applies regardless of dose.

Anyone experiencing side effects significant enough to consider dose-reduction should speak to a prescriber rather than adjusting the pen themselves. Severe or persistent stomach pain, particularly if it radiates to the back, warrants urgent medical attention and should not be managed by lowering the dose at home. You can also report unexpected reactions via the MHRA Yellow Card scheme.

What a licensed approach to managing side effects actually looks like

The most common reason people look up microdosing is nausea. It is the single side effect that most often tempts people to reach for a lower dose. There are licensed and evidence-supported ways to manage it: eating smaller, lower-fat meals; staying well hydrated; avoiding lying down after eating; and sometimes slowing the titration timeline, all done with a prescriber's input.

At nume, every repeat order goes through a fresh clinical review. If a patient is struggling at a given dose, our prescribers can extend the time at that level rather than simply escalating, that is standard clinical practice, not a workaround. It is worth knowing that this kind of flexibility exists before deciding to self-manage with an improvised sub-dose, and if you want a step-by-step guide to microdosing semaglutide and how that process actually works, that page walks through it clearly. If you want to explore what the right weight-loss treatment approach looks like for your situation, a consultation is the sensible first step. Our clinical team handles these conversations every day, the question of 'can I go slower?' is one our prescribers hear most weeks.

For a fuller picture of how unofficial dose adjustments compare with the licensed schedule, the microdosing Wegovy page covers the topic in more depth, and if you are weighing up the practical and cost implications, the Wegovy prices page gives honest context on what legitimate private treatment costs.